Patents Examined by Paul J Holland
  • Patent number: 12037627
    Abstract: A Lactobacillus paracasei and uses thereof. The Lactobacillus paracasei has a deposit number of CGMCC No. 14813. The Lactobacillus paracasei can be used for increasing the amount of an organic acid in a raw material. The Lactobacillus paracasei can be used for fermenting the raw material, where the raw material can be selected from at least one of fruits, which can increase the content of the organic acid in a fermented product.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: July 16, 2024
    Assignee: CHINA NATIONAL RESEARCH INSTITUTE OF FOOD & FERMENTATION INDUSTRIES CO., LTD.
    Inventors: Muyi Cai, Ruizeng Gu, Jun Lu, Kong Ling, Lu Lu, Ming Zhou, Xinyue Cui, Xingchang Pan, Zhe Dong, Yong Ma, Yaguang Xu, Yongqing Ma, Liang Chen, Ying Wei, Haixin Zhang, Yan Liu, Kelu Cao, Jing Wang, Guoming Li, Yuchen Wang, Yuqing Wang, Yuan Bi, Xiuyuan Qin
  • Patent number: 12031151
    Abstract: Methods of improving recombinant protein titer and cell titer in cell culture using cell culture media having reduced impurities are provided, and well as cell culture media having reduced impurities that can used for the production of a recombinant protein and cells with improved titer. The cell culture media having reduced impurities comprises a HEPES buffer, and the reduced impurities are HEPES related impurities. In certain aspects, methods and media improve protein titer, cell growth, and/or viable cell density.
    Type: Grant
    Filed: January 19, 2022
    Date of Patent: July 9, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Reginald Smith, Sarah Nicoletti, Victor Shashilov, Hongxia Wang, Jikang Wu, Abdelqader Zamamiri
  • Patent number: 12031169
    Abstract: Provided herein are compounds, compositions, and methods for recovery of one or more water-immiscible compounds from microbial biomass.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: July 9, 2024
    Assignee: Amyris, Inc.
    Inventors: Ronald Ray Henry, Joshua Steven Leng
  • Patent number: 12031112
    Abstract: Detergent compositions that include a lipase variant of a parent lipase which has lipase activity and includes one or more substitutions corresponding to G23S, D27N, A40, F51I,L, E56R, D57N, V60E,K, K98I, N101D, R118, G163S, T231R, N233R, Y220F, T244E, and P256T using SEQ ID NO: 2 for numbering. Water-soluble unit dose articles including water-soluble film and a detergent composition including lipase variants. Methods of cleaning and/or treatment of surfaces using such compositions.
    Type: Grant
    Filed: February 25, 2022
    Date of Patent: July 9, 2024
    Assignee: The Procter & Gamble Company
    Inventors: Steven George Patterson, Nazarmohammad Gulamhussain Momin, Miguel D. G. P. Toscano, Thomas A. Poulsen, Carsten H. Hansen, Lone Baunsgaard, Keith Gibson
  • Patent number: 12031164
    Abstract: Fusion proteins containing a targeting sequence, exosporium protein, or exosporium protein fragment that targets the fusion protein to the exosporium of a recombinant Bacillus cereus family member are provided. The fusion proteins further comprise an enzyme having ACC deaminase activity, a phospholipase, a lipase, a xylanase, a xylosidase, a lactonase, a chitosanase, a protease, a glucanase, a phytase, an acid phosphatase, a pectinase, a mannanase, and/or an expansin protein. Also provided are recombinant Bacillus cereus family members that express the fusion proteins, exosporium fragments derived from the recombinant Bacillus cereus family members, and formulations containing the recombinant Bacillus cereus family members or exosporium fragments. Plant seeds treated with the recombinant Bacillus cereus family members, exosporium fragments, or formulations are also provided.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: July 9, 2024
    Assignee: Spogen Biotech Inc.
    Inventors: Brian M. Thompson, Jorg Augustin, Ashley Siegel
  • Patent number: 12016908
    Abstract: The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.
    Type: Grant
    Filed: July 26, 2022
    Date of Patent: June 25, 2024
    Assignee: Beam Therapeutics Inc.
    Inventors: Ian Slaymaker, Nicole Gaudelli, Yi Yu, Bernd Zetsche, David A. Born, Seung-Joo Lee, Michael Packer
  • Patent number: 12012610
    Abstract: The present invention relates to A multicomponent system wherein a first component is an engineered antigen-presenting cell (eAPC) designated component A and a second component is a genetic donor vector, designated component C, for delivery of one or more ORFs encoding an analyte antigen-presenting complex (aAPX) and/or an analyte antigenic molecule (aAM), wherein component A a. Lacks endogenous surface expression of at least one family of aAPX and/or aAM and b. Contains at least two genomic receiver GO sites, designated component B and component D, each for integration of at least one ORF encoding at least one aAPX and/or aAM, and component C is matched to a component B, and wherein component C is designed to deliver c. A single ORF encoding at least one aAPX and/or aAM or d. Two or more ORF encoding at least one aAPX and/or aAM, wherein the genomic receiver sites B and D are synthetic constructs designed for re-combinase mediated exchange (RMCE).
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: June 18, 2024
    Assignee: Genovie AB
    Inventors: Reagan Micheal Jarvis, Ryan Edward Hill, Luke Benjamin Pase
  • Patent number: 12004514
    Abstract: Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar activity. This invention is directed to compositions enriched for particular occidiofungin diastereomers/conformers, methods of making compositions enriched for particular diastereomers/conformers and microorganisms suitable for producing enriched compositions of particular diastereomers/conformers. Methods of treating fungal infections or plants infected by fungi are also provided.
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: June 11, 2024
    Assignees: The Texas A&M University System, Mississippi State University
    Inventors: James Leif Smith, Akshaya Ravichandran, Shien Lu, Ganyu Gu
  • Patent number: 11999943
    Abstract: Methods of redirecting carbon flux and increasing C2/C3 or a C4/5/6 carbon chain length carbon-based chemical product yield in an organism, nonnaturally occurring organisms with redirected carbon flux and increased C2/C3 or C4/5/6 carbon chain length carbon-based chemical product yield and methods for using these organisms in production of C2/C3 or C4/5/6 carbon chain length carbon-based chemical products are provided.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: June 4, 2024
    Assignee: INV NYLON CHEMICALS AMERICAS, LLC
    Inventors: Alexander Brett Foster, Emilie Sophie Fritsch
  • Patent number: 11999947
    Abstract: The disclosure provides adenosine deaminases that are capable of deaminating adenosine in DNA. The disclosure also provides fusion proteins comprising a Cas9 (e.g., a Cas9 nickase) domain and adenosine deaminases that deaminate adenosine in DNA. In some embodiments, the fusion proteins further comprise a nuclear localization sequence (NLS), and/or an inhibitor of base repair, such as, a nuclease dead inosine specific nuclease (dISN).
    Type: Grant
    Filed: February 24, 2023
    Date of Patent: June 4, 2024
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, Nicole Gaudelli
  • Patent number: 11970710
    Abstract: Disclosed herein are Type I Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) system related compositions and methods of using said Type I CRISPR/Cas system related compositions for altering gene expression and genome engineering. The invention relates to compositions comprising Type I CRISPR-Cas polypeptides and CRISPR array nucleic acids designed for genome modification in eukaryotic cells and for targeted killing of eukaryotic cells.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: April 30, 2024
    Assignees: Duke University, North Carolina State University
    Inventors: Charles A. Gersbach, Adrian Pickar Oliver, Chase Beisel
  • Patent number: 11959094
    Abstract: Disclosed herein are homology-independent targeted integration methods of integrating an exogenous DNA sequence into a genome of a non-dividing cell and compositions for such methods. Methods herein comprise contacting the non-dividing cell with a composition comprising a targeting construct comprising the exogenous DNA sequence and a targeting sequence, a complementary strand oligonucleotide homologous to the targeting sequence, and a nuclease, thereby altering the genome of the non-dividing cell.
    Type: Grant
    Filed: May 2, 2023
    Date of Patent: April 16, 2024
    Assignee: Salk Institute for Biological Studies
    Inventors: Juan Carlos Izpisua Belmonte, Keiichiro Suzuki, Reyna Hernandez-Benitez, Jun Wu, Yuji Tsunekawa
  • Patent number: 11952570
    Abstract: Methods are provided for the isolation and analysis of circular DNA from complex samples, based on the topology of the DNA molecule. A sample comprising DNA species is combined with a chaotropic dense salt solution. A fraction containing the circular DNA of interest is isolated and dialyzed to remove excess salt. In some embodiments salt gradients are generated by ultracentrifugation in the absence of intercalating dyes, e.g. ethidium bromide; and in the absence of protease digestion. The circular DNA thus isolated is substantially pure, e.g. greater than about 75%, greater than about 80%, greater than about 90%, greater than about 95% of DNA in the isolated fraction is comprised of circular DNA.
    Type: Grant
    Filed: January 18, 2023
    Date of Patent: April 9, 2024
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Massa Shoura, Stephen Levene, David Girata
  • Patent number: 11946085
    Abstract: The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.
    Type: Grant
    Filed: April 13, 2023
    Date of Patent: April 2, 2024
    Assignee: Amgen Inc.
    Inventors: Chung-Jr Huang, Xiaoming Yang
  • Patent number: 11946040
    Abstract: Engineered adenine base editor (ABE) variants with reduced RNA editing activity, and methods of using the same.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: April 2, 2024
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Julian Grunewald, Ronghao Zhou
  • Patent number: 11939611
    Abstract: The present disclosure describes biocatalytic processes for producing a product, comprising providing an aqueous stream (AS) comprising at least one fermentable substrate and a gaseous stream (GS) comprising at least one of CO2/H2, H2, methane, and/or CO to a fermentation zone, wherein the GS and AS stream are optionally contacted and/or mixed; the fermentation zone comprising at least one organism capable of metabolizing an AS substrate and a GS substrate, wherein the fermentation operates at conditions to mixotrophically metabolize at least one gaseous substrate in the GS and at least one substrate in the AS, producing the product.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: March 26, 2024
    Assignee: INV NYLON CHEMICALS AMERICAS, LLC
    Inventors: Gary Smith, Alex Van Eck Conradie, Gregory S. Kirby, Paul S. Pearlman
  • Patent number: 11932886
    Abstract: Provided are amino acid sequences of engineered transaminase polynucleotide that are useful for asymmetrically synthesizing chiral amine compounds, and its preparation process and reaction process under industrial-relevant conditions. Also provided are polynucleotide sequences encoding engineered transaminase polypeptides, engineered host cells capable of expressing engineered transaminase polypeptides, and methods of producing chiral amine compounds using engineered transaminase polypeptides. Compared to other enzymes, the engineered transaminase polypeptides provided by this invention have better catalytic activity and stability, and are not inhibited by chiral amine products in the synthesis process. The use of the engineered polypeptides of the present invention for the preparation of chiral amine compound results in higher unit activity, and has good industrial application prospects.
    Type: Grant
    Filed: December 22, 2018
    Date of Patent: March 19, 2024
    Assignee: ENZYMASTER (NINGBO) BIO-ENGINEERING CO., LTD.
    Inventors: Haibin Chen, Yong Koy Bong, Juanjuan Wang, Baoqin Cai, Chuanyang Shang, Marco Bocola
  • Patent number: 11926857
    Abstract: The present disclosure provides acyltransferases useful for synthesizing therapeutically important statin compound.
    Type: Grant
    Filed: May 25, 2021
    Date of Patent: March 12, 2024
    Assignee: Codexis, Inc.
    Inventors: Lynne Gilson, Steven J. Collier, Joly Sukumaran, Wan Lin Yeo, Oscar Alvizo, Ee Ling Teo, Robert J. Wilson, Junye Xu
  • Patent number: 11920128
    Abstract: The invention relates to an approach for introducing one or more desired insertions and/or deletions of known sizes into one or more predefined locations in a nucleic acid (eg, in a cell or organism genome). They developed techniques to do this either in a sequential fashion or by inserting a discrete DNA fragment of defined size into the genome precisely in a predefined location or carrying out a discrete deletion of a defined size at a precise location. The technique is based on the observation that DNA single-stranded breaks are preferentially repaired through the HDR pathway, and this reduces the chances of indels (eg, produced by NHEJ) in the present invention and thus is more efficient than prior art techniques. The invention also provides sequential insertion and/or deletions using single- or double-stranded DNA cutting.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: March 5, 2024
    Assignee: Kymab Limited
    Inventors: Allan Bradley, Hanif Ali, E-Chiang Lee
  • Patent number: 11920148
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with ANGPTL3 whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of ANGPTL3 gene in a cell by genome editing.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: March 5, 2024
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan, Yvonne Sarah Aratyn